A CONTROLLED PROSPECTIVE STUDY OF TRANSFUSION-ASSOCIATED HEPATITIS

本研究调查了输血后肝炎（PTH）的发病率 在前瞻性随访的心脏直视手术患者中， 禁止传染性献血者的措施。 这些措施包括 连续检测供体的丙氨酸氨基转移酶（ALT）、抗体 抗人类免疫缺陷病毒（抗HIV-1）、抗B型肝炎抗体 核心抗原（抗HBC）和丙型肝炎病毒抗体（抗HCV） 以及密集的捐赠者询问记录到高风险行为。 在1985年至1990年期间，肝炎发病率从10%下降到大约 百分之三 随着第一代抗-HCV检测的推出， 发病率降至1.5%以下。 我们现在正在跟踪PTH发病率， 第二代抗HCV检测试剂盒的使用和使用率正在接近 300个接受者中的零个。 超过95%的PTH被归类为非 A，非乙型肝炎，其中约90%与HCV有关。 因为关闭的！D心脏直视手术计划，这些研究是 在乔治敦大学医院（GUH）和费尔法克斯进行 医院

This study investigates the incidence of post-transfusion hepatitis (PTH) in prospectively followed open-heart surgery patients following a variety of measures to interdict infectious donors. These measures have included sequential testing of donors for alanine aminotransferase (ALT), antibody to the Human Immunodeficiency Virus (anti-HIV-1), antibody to hepatitis B core antigen (anti-HBC) and antibody to the hepatitis C virus (anti-HCV) as well as intensive donor questioning in record to high-risk behavior. Between 1985 and 1990, hepatitis incidence fell from 10% to approximately 3%. Following the introduction of First Generation anti-HCV testing incidence fell to under 1.5%. We are now following PTH incidence after the use of Second Generation anti-HCV assays and rates are approaching zero among 300 recipients. Greater than 95% of PTH is classified as non- A, non-B hepatitis and approximately 90% of this is HCV related. Because of closure of the !D open heart surgery program, these studies are being conducted at Georgetown University Hospital (GUH) and Fairfax Hospital.